Activation of AMPK inhibits PDGF-induced pulmonary arterial smooth muscle cells proliferation and its potential mechanisms

Song, Yang; Wu, Yuanyuan; Su, Xiaofan; Zhu, Yanting; Liu, Lu; Pan, Yilin; Zhu, Bo; Yang, Lan; Gao, Li; Li, Manxiang

doi:10.1016/j.phrs.2016.03.010

Cited by 41 publications

(33 citation statements)

References 40 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have shown that AMPK promotes SMC proliferation and the development of pulmonary hypertension, which was reversed with AMPK inhibition (Ibe et al, 2013;Moral-Sanz et al, 2016). Conversely, other studies have shown that AMPK activation reduced SMC proliferation and vascular remodeling and may be protective against the development of hypoxia-induced pulmonary hypertension (Agard et al, 2009;Dean et al, 2016;Song et al, 2016). Importantly, in our present study, hPASMC proliferation was decreased with AMPK activation by AICAR ( Figure 6).…”

Section: F I G U R Esupporting

confidence: 53%

“…Whereas NO acts as both a target and an effector of the AMPK pathway in endothelial cells (Fisslthaler & Fleming, 2009;Suzuki et al, 2008), less is known about the mechanism by which NO regulates AMPK in smooth muscle cells. Moreover, data on the role of AMPK in vascular proliferation and pulmonary hypertension are conflicting (Agard et al, 2009;Dean, Nilsen, Loughlin, Salt, & MacLean, 2016;Ibe et al, 2013;Moral-Sanz et al, 2016;Salt & Hardie, 2017;Song et al, 2016). Several studies have shown that AMPK promotes SMC proliferation and the development of pulmonary hypertension, which was reversed with AMPK inhibition (Ibe et al, 2013;Moral-Sanz et al, 2016).…”

Section: F I G U R Ementioning

confidence: 99%

See 1 more Smart Citation

Nitric oxide activates AMPK by modulating PDE3A in human pulmonary artery smooth muscle cells

et al. 2020

View full text Add to dashboard Cite

Phosphodiesterase 3 (PDE3), of which there are two isoforms, PDE3A and PDE3B, hydrolyzes cAMP and cGMP—cyclic nucleotides important in the regulation of pulmonary vascular tone. PDE3 has been implicated in pulmonary hypertension unresponsive to nitric oxide (NO); however, contributions of the two isoforms are not known. Furthermore, adenosine monophosphate‐activated protein kinase (AMPK), a critical regulator of cellular energy homeostasis, has been shown to be modulated by PDE3 in varying cell types. While AMPK has recently been implicated in pulmonary hypertension pathogenesis, its role and regulation in the pulmonary vasculature remain to be elucidated. Therefore, we utilized human pulmonary artery smooth muscle cells (hPASMC) to test the hypothesis that NO increases PDE3 expression in an isoform‐specific manner, thereby activating AMPK and inhibiting hPASMC proliferation. We found that in hPASMC, NO treatment increased PDE3A protein expression and PDE3 activity with a concomitant decrease in cAMP concentrations and increase in AMPK phosphorylation. Knockdown of PDE3A using siRNA transfection blunted the NO‐induced AMPK activation, indicating that PDE3A plays an important role in AMPK regulation in hPASMC. Treatment with a soluble guanylate cyclase (sGC) stimulator increased PDE3A expression and AMPK activation similar to that seen with NO treatment, whereas treatment with a sGC inhibitor blunted the NO‐induced increase in PDE3A and AMPK activation. These results suggest that NO increases PDE3A expression, decreases cAMP, and activates AMPK via the sGC‐cGMP pathway. We speculate that NO‐induced increases in PDE3A and AMPK may have implications in the pathogenesis and the response to therapies in pulmonary hypertensive disorders.

show abstract

Section: F I G U R Esupporting

confidence: 53%

Section: F I G U R Ementioning

confidence: 99%

Nitric oxide activates AMPK by modulating PDE3A in human pulmonary artery smooth muscle cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Our ssGSEA/GSEA analysis showed that the "metformin_downregulated" signature and NFkB signaling exhibited a good consistency with the activated stromal fibroblast phenotype corresponding to the acknowledged pathway characteristically activated in CAFs (46) such as TGFb, IGF1/PI3K/mTOR, PDGF, and the JAK/STAT signaling. Actually, all these signaling factors associated with CAFs activation have been reported to be inhibited by metformin in fibroblasts or other cells (23,45,54,60,61). These preliminary results indicate that metformin will likely exert a multiple reprogramming of CAFs in ovarian cancer.…”

Section: Discussionmentioning

confidence: 71%

Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer

Yang

Park

et al. 2018

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Ovarian cancer is a devastating disease due to its high incidence of relapse and chemoresistance. The tumor microenvironment, especially the tumor stroma compartment, was proven to contribute tremendously to the unsatisfactory chemotherapeutic efficacy in ovarian cancer. Cytotoxic agents not only effect tumor cells, but also modulate the phenotype and characteristics of the vast stromal cell population, which can in turn alter the tumor cell response to chemointervention. In this study, we focused on the tumor stroma response to cytotoxic agents and the subsequent effect on the ovarian cancer tumor cells. First, we found a significant stromal overexpression of IL6 in patient samples that received cisplatin-based treatment, which was further validated in purified fibroblasts challenged with cisplatin. Stromal fibroblast-derived IL6 was proven to mediate ovarian cancer tumor cell chemoresistance. For the first time, we found that the tumor stroma of patients with routine metformin administration exhibited lower IL6 expression. Thus, we presumed that metformin was a potent alleviator of stromal inflammation in ovarian cancer. We found that metformin partly reversed cisplatin-stimulated IL6 secretion in the stromal fibroblasts and attenuated fibroblast-facilitated tumor growth in 3D organotypic cocultures and murine xenograft models. Mechanistically, we found that metformin inhibited IL6 secretion via suppressing NFκB signaling, an upstream controller of stromal inflammation. Collectively, our findings introduced a novel mechanism of metformin in suppressing ovarian cancer progression through diminishing chemotherapy-induced stromal activation. Therefore, we provide an alternative therapeutic option in targeting stromal inflammation and a potential scheme of combination therapy to improve the chemosensitivity in ovarian cancer. .

show abstract

“…We found that TGF-betaR1 and smad4 were possible downstream targets of miR-140-5p, reduction in miR-140-5p in PAH might stimulate TGF-beta1/Smad4 pathway by upregulating TGF-betaR1 and smad4. Previous studies have demonstrated that PDGF, TLR4, VEGFA, and FGF contribute to the pathogenesis of PAH via activating various signaling pathways, especially PI3K/Akt cascade [24][25][26][27][28]. CREB, an important transcription factor lying downstream of PI3K/Akt pathway, mediates the partial functions of PI3K/Akt [29].…”

Section: Discussionmentioning

confidence: 99%

Prediction of target genes for miR‐140‐5p in pulmonary arterial hypertension using bioinformatics methods

Shi

Wan

et al. 2017

FEBS Open Bio

Self Cite

View full text Add to dashboard Cite

The expression of micro RNA (miR)‐140‐5p is known to be reduced in both pulmonary arterial hypertension ( PAH ) patients and monocrotaline‐induced PAH models in rat. Identification of target genes for miR‐140‐5p with bioinformatics analysis may reveal new pathways and connections in PAH . This study aimed to explore downstream target genes and relevant signaling pathways regulated by miR‐140‐5p to provide theoretical evidences for further researches on role of miR‐140‐5p in PAH . Multiple downstream target genes and upstream transcription factors ( TF s) of miR‐140‐5p were predicted in the analysis. Gene ontology ( GO ) enrichment analysis indicated that downstream target genes of miR‐140‐5p were enriched in many biological processes, such as biological regulation, signal transduction, response to chemical stimulus, stem cell proliferation, cell surface receptor signaling pathways. Kyoto Encyclopedia of Genes and Genome ( KEGG ) pathway analysis found that downstream target genes were mainly located in Notch, TGF ‐beta, PI 3K/Akt, and Hippo signaling pathway. According to TF –mi RNA – mRNA network, the important downstream target genes of miR‐140‐5p were PPI , TGF ‐betaR1, smad4, JAG 1, ADAM 10, FGF 9, PDGFRA , VEGFA , LAMC 1, TLR 4, and CREB . After thoroughly reviewing published literature, we found that 23 target genes and seven signaling pathways were truly inhibited by miR‐140‐5p in various tissues or cells; most of these verified targets were in accordance with our present prediction. Other predicted targets still need further verification in vivo and in vitro .

show abstract

Activation of AMPK inhibits PDGF-induced pulmonary arterial smooth muscle cells proliferation and its potential mechanisms

Cited by 41 publications

References 40 publications

Nitric oxide activates AMPK by modulating PDE3A in human pulmonary artery smooth muscle cells

Nitric oxide activates AMPK by modulating PDE3A in human pulmonary artery smooth muscle cells

Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer

Prediction of target genes for miR‐140‐5p in pulmonary arterial hypertension using bioinformatics methods

Contact Info

Product

Resources

About